| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/03/2006 | CA2288241C Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination |
| 10/03/2006 | CA2288046C Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| 10/03/2006 | CA2279535C Dermatan disulfate, an inhibitor of thrombin generation and complement activation |
| 10/03/2006 | CA2277949C Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions |
| 10/03/2006 | CA2277018C Use of angiotensin ii antagonists to treat symptomatic heart failure |
| 10/03/2006 | CA2275419C Mucosal administration of substances to mammals |
| 10/03/2006 | CA2268840C Benzimidazole-2-carbamates for the treatment of viral infections and cancer |
| 10/03/2006 | CA2261259C Alpha-amino acid amides, preparation thereof and the therapeutical use thereof |
| 10/03/2006 | CA2256897C Morphinan derivatives and medical uses |
| 10/03/2006 | CA2253580C Improvements in or relating to compositions containing creatine |
| 10/03/2006 | CA2252394C Hydrolyzed cellulose granulations for pharmaceuticals |
| 10/03/2006 | CA2251840C Composition, barrier film, and method for preventing contact dermatitis |
| 10/03/2006 | CA2250906C Enteric-coated pharmaceutical compositions of mycophenolate |
| 10/03/2006 | CA2250115C Fast disintegrating oral dosage form |
| 10/03/2006 | CA2249654C Benzoxazines for enhancing synaptic response |
| 10/03/2006 | CA2249348C Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide |
| 10/03/2006 | CA2247946C Anticachectic composition |
| 10/03/2006 | CA2234638C New bis-platinum complexes with polymethylene derivatives as ligands having antitumor activity |
| 10/03/2006 | CA2231633C Process for the preparation of anti-malarial drugs |
| 10/03/2006 | CA2225741C Ionophore antibiotic formulations |
| 10/03/2006 | CA2224764C A process for preparing epirubicin or acid addition salts thereof from daunorubicin |
| 10/03/2006 | CA2215319C Compositions comprising nicotinylalanine and an inhibitor of glycine conjugation or vitamin b6 |
| 10/03/2006 | CA2213842C Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence |
| 10/03/2006 | CA2213794C Preventive or therapeutic drug for alzheimer's disease |
| 10/03/2006 | CA2213188C Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| 10/03/2006 | CA2212440C Pharmaceutical preparations for tnf inhibition |
| 10/03/2006 | CA2208611C 4-amino-2-ureidopyrimidine-5-carboxamides, processes for their preparation, pharmaceuticals comprising these compounds, and their use |
| 10/03/2006 | CA2189221C Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them |
| 10/03/2006 | CA2187130C Novel sulphonamides |
| 10/03/2006 | CA2151507C Pharmaceutical composition containing bicyclic type compounds |
| 10/03/2006 | CA2148942C M-edta pharmaceutical preparations and uses thereof |
| 10/03/2006 | CA2082495C A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
| 10/01/2006 | CA2541379A1 Losartan potassium crystalline form alpha |
| 09/30/2006 | CA2503087A1 Intravenous formulations of pyridoxal 5'-phosphate and method of preparation |
| 09/29/2006 | CA2554633A1 Galenic formulations of organic compounds |
| 09/28/2006 | WO2006102674A2 Diphenylheterocycle cholesterol absorption inhibitors |
| 09/28/2006 | WO2006102647A1 20-alkyl, gemini vitamin d3 compounds and methods of use thereof |
| 09/28/2006 | WO2006102645A1 Biaryl derived amide modulators of vanilloid vr1 receptor |
| 09/28/2006 | WO2006102611A2 Therapeutic agents for the treatment of leukemia |
| 09/28/2006 | WO2006102604A2 Topical formulations of borinic acid antibodies and their methods of use |
| 09/28/2006 | WO2006102594A1 Nucleoside prodrugs for treating viral infections |
| 09/28/2006 | WO2006102576A1 Water-dispersible carotenoids, including analogs and derivatives |
| 09/28/2006 | WO2006102535A2 Sulfonyl containing compounds as cysteine protease inhibitors |
| 09/28/2006 | WO2006102533A2 Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates |
| 09/28/2006 | WO2006102530A1 Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery |
| 09/28/2006 | WO2006102483A2 Modulation of aquaporin in modulaton of angiogenesis and cell migration |
| 09/28/2006 | WO2006102476A2 Compositions and methods for ameliorating cachexia |
| 09/28/2006 | WO2006102447A2 Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers |
| 09/28/2006 | WO2006102439A2 Treatment or prevention of cancer and precancerous disorders |
| 09/28/2006 | WO2006102426A2 Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders |
| 09/28/2006 | WO2006102410A2 Minimally invasive clinical treatment method for closure of umbilical hernias |
| 09/28/2006 | WO2006102375A2 Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer |
| 09/28/2006 | WO2006102363A1 Methods for treating or preventing acute myelogenous leukemia |
| 09/28/2006 | WO2006102345A2 Methods and systems for operating an aerosol generator |
| 09/28/2006 | WO2006102333A2 Ophthalmic use of agents which inhibit connective tissue growth factor binding and signalling via the trka/p75ntr receptor complex |
| 09/28/2006 | WO2006102308A2 Beta-lactamyl vasopressin v1b antagonists |
| 09/28/2006 | WO2006102283A2 Beta-lactamylalkanoic acids for treating premenstrual disorders |
| 09/28/2006 | WO2006102243A2 Alpha ketoamide compounds as cysteine protease inhibitors |
| 09/28/2006 | WO2006102232A2 Dosing regimes for trans-clomiphene |
| 09/28/2006 | WO2006102195A1 3-pyridinecarboxamide reduces nerve degeneration |
| 09/28/2006 | WO2006102194A1 Imidazopyridazine compounds |
| 09/28/2006 | WO2006102176A2 Process for preparing crystalline form i of olanzapine |
| 09/28/2006 | WO2006102167A2 Compounds for tissue imaging and methods of use thereof |
| 09/28/2006 | WO2006102159A2 Compounds and methods for the treatment of malaria and cancer |
| 09/28/2006 | WO2006102126A2 Inhibitors of isoprenylcysteine carboxyl methyltransferase |
| 09/28/2006 | WO2006102117A1 Nanoparticulate biphosphonate compositions |
| 09/28/2006 | WO2006102112A2 Prokineticin 1 receptor |
| 09/28/2006 | WO2006102108A2 Fucoidan compositions and methods for dietary and nutritional supplements |
| 09/28/2006 | WO2006102102A2 Tgf-beta modulators and methods for using the same |
| 09/28/2006 | WO2006102097A2 Synthesis of avrainvillamide, stephacidin b, and analogues thereof |
| 09/28/2006 | WO2006102093A1 Gaboxadol forms, compositions thereof, and related methods |
| 09/28/2006 | WO2006102079A1 N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| 09/28/2006 | WO2006102060A1 Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin |
| 09/28/2006 | WO2006102029A2 Methods and compositions for the treatment of urinary incontinence |
| 09/28/2006 | WO2006102004A2 A stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same |
| 09/28/2006 | WO2006101977A2 Pyrimidine compounds and methods of use |
| 09/28/2006 | WO2006101954A2 Interstitial cystitis treatment |
| 09/28/2006 | WO2006101950A2 Pxr agonists for cardiovascular disease |
| 09/28/2006 | WO2006101945A2 Agglomerated starch compositions |
| 09/28/2006 | WO2006101940A2 Composition comprising n-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof |
| 09/28/2006 | WO2006101937A1 Acylhydrazones as kinase modulators |
| 09/28/2006 | WO2006101922A2 Medicinal compositions of salts, chelates and/or free acids of alpha hydroxyl organic acids and related processes and methods |
| 09/28/2006 | WO2006101920A2 Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage |
| 09/28/2006 | WO2006101911A1 Selective inhibitors of translesion dna replication |
| 09/28/2006 | WO2006101903A1 Dipyrazoles as central nervous system agents |
| 09/28/2006 | WO2006101867A2 Treatment of inflammatory bowel disease |
| 09/28/2006 | WO2006101864A1 Antibacterial 5',5-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy- 1,1'-biphenyl compounds and related methods |
| 09/28/2006 | WO2006101860A1 Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
| 09/28/2006 | WO2006101859A2 Piperidinyl substituted cyclohexane-1,4-diamines |
| 09/28/2006 | WO2006101858A1 Alpha-helix mimetics and methods relating to the treatment of fibrosis |
| 09/28/2006 | WO2006101846A1 Dosing regimen of flavopiridol for treating cancer in particular cll |
| 09/28/2006 | WO2006101845A2 Synthesis and purification of pteroic acid and conjugates thereof |
| 09/28/2006 | WO2006101839A2 Enhanced bimatoprost ophthalmic solution |
| 09/28/2006 | WO2006101818A1 Antibacterial 3',5-disubstituted 2,4'-dihydroxybiphenyl compounds, derivatives and related methods |
| 09/28/2006 | WO2006101808A1 Pyrrolidine derivatives as histamine h3 receptor antagonists |
| 09/28/2006 | WO2006101794A2 Stable tablet dosage forms of proton pump inhibitors |
| 09/28/2006 | WO2006101783A2 Compounds and compositions as protein kinase inhibitors |
| 09/28/2006 | WO2006101780A1 Mitotic kinesin inhibitors |
| 09/28/2006 | WO2006101761A2 Mitotic kinesin inhibitors |
| 09/28/2006 | WO2006101706A1 Health-related liquid compositions |